{"entity":{"id":"nct06311695","kind":"trial","name":"Contrast-Enhanced Spectral Mammography (CESM)","aka":[],"tldr":"A phase 2 trial of Contrast-enhanced mammography in Breast cancer, run by European Institute of Oncology, with a status the registry has not verified recently.","summary":"Contrast-Enhanced Spectral Mammography (CESM) is a phase 2 interventional study registered as NCT06311695 by European Institute of Oncology, with 263 participants planned, started 2020-11-16 and due to reach its primary completion in 2025-02-28. Interventions recorded: Contrast Enhanced Mammography. Conditions recorded: Breast Cancer.\n\nLinked to the technology Contrast-enhanced mammography because the registry names it (\"contrast enhanced mammography\") among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT06311695","url":"https://clinicaltrials.gov/study/NCT06311695"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":["contrast-enhanced-mammography"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06311695","phase":"2","setting":"The Role of Contrast-Enhanced Spectral Mammography (CESM) in the Diagnostic Process of Breast Cancer","sponsor":"European Institute of Oncology","enrolled":263,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06311695/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"technology":[{"id":"contrast-enhanced-mammography","kind":"technology","name":"Contrast-enhanced mammography","route":"/technologies/contrast-enhanced-mammography/"}]}}